CO4820397A1 - TREATMENT AGAINST ASTHMA WITH TNFR -Ig - Google Patents

TREATMENT AGAINST ASTHMA WITH TNFR -Ig

Info

Publication number
CO4820397A1
CO4820397A1 CO97024335A CO97024335A CO4820397A1 CO 4820397 A1 CO4820397 A1 CO 4820397A1 CO 97024335 A CO97024335 A CO 97024335A CO 97024335 A CO97024335 A CO 97024335A CO 4820397 A1 CO4820397 A1 CO 4820397A1
Authority
CO
Colombia
Prior art keywords
igg
preparation
patient
fighting
aim
Prior art date
Application number
CO97024335A
Other languages
Spanish (es)
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO4820397A1 publication Critical patent/CO4820397A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para combatir el asma en pacientes que sufran de unestado asmático, el cual método incluye la administración a dicho paciente de una composición que contiene una preparación compuesta por una o más proteínas en quiméricas de unión a TNF-a, cada una de las cuales proteínas en dicha preparación esta compuesta por la porción soluble de la proteína receptora de TNF p55 fusionada a una IgG, en la que dicha IgG fusionada contiene todos los dominios de IgG excepto el primer dominio de IgG de la región constante de la cadena pesada de la IgG, conteniendo dicha composición un vector farmacéutico terapéuticamente inerte, y siendo dicha preparación administrada a dicho paciente con el objetivo de suministrar a dicho paciente una cantidad efectiva de dicha preparación de proteína quimérica, con el objetivo de combatir dicho estado asmático.A method of fighting asthma in patients suffering from an asthmatic state, which method includes administering to said patient a composition containing a preparation consisting of one or more TNF-α binding chimeric proteins, each of which Proteins in said preparation is composed of the soluble portion of the TNF receptor protein p55 fused to an IgG, in which said fused IgG contains all the IgG domains except the first IgG domain of the constant region of the heavy chain of the IgG, said composition containing a therapeutically inert pharmaceutical vector, and said preparation being administered to said patient with the aim of supplying said patient with an effective amount of said chimeric protein preparation, with the aim of fighting said asthmatic state.

CO97024335A 1996-05-08 1997-05-07 TREATMENT AGAINST ASTHMA WITH TNFR -Ig CO4820397A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
CO4820397A1 true CO4820397A1 (en) 1999-07-28

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97024335A CO4820397A1 (en) 1996-05-08 1997-05-07 TREATMENT AGAINST ASTHMA WITH TNFR -Ig

Country Status (15)

Country Link
EP (1) EP0910413A2 (en)
JP (1) JP2000510113A (en)
KR (1) KR20000010825A (en)
CN (1) CN1233189A (en)
AR (1) AR007020A1 (en)
AU (1) AU725408B2 (en)
BR (1) BR9708928A (en)
CA (1) CA2253557A1 (en)
CO (1) CO4820397A1 (en)
HR (1) HRP970224A2 (en)
MA (1) MA24169A1 (en)
PE (1) PE70698A1 (en)
TR (1) TR199802238T2 (en)
WO (1) WO1997041895A2 (en)
ZA (1) ZA973843B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2316545A1 (en) * 1997-12-29 1999-07-08 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
TR200504220T2 (en) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
ES2304602T3 (en) * 2003-02-28 2008-10-16 Ares Trading S.A. LIQUID FORMULATIONS OF THE UNION PROTEIN TO THE TBP-1 TUMOR NECROSIS FACTOR.
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2009004134A (en) 2006-10-20 2009-08-12 Biogen Idec Inc Treatment of demyelinating disorders.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (en) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-binding proteins
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
BR9508419A (en) * 1994-07-22 1997-11-18 Hoffmann La Roche Pharmaceutical compositions comprising a cholinergic tnf binding protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
BR9708928A (en) 2000-05-09
MA24169A1 (en) 1997-12-31
PE70698A1 (en) 1998-11-18
KR20000010825A (en) 2000-02-25
EP0910413A2 (en) 1999-04-28
CN1233189A (en) 1999-10-27
AR007020A1 (en) 1999-10-13
TR199802238T2 (en) 1999-02-22
HRP970224A2 (en) 1998-04-30
AU2776497A (en) 1997-11-26
ZA973843B (en) 1997-11-10
AU725408B2 (en) 2000-10-12
WO1997041895A2 (en) 1997-11-13
JP2000510113A (en) 2000-08-08
WO1997041895A3 (en) 1998-03-12
CA2253557A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
GB2301366B (en) Antibodies against E-selectin
HK1022440A1 (en) Combination therapy using a tnf binding protein for treating tnf-mediated diseases
DK0914144T3 (en) Therapeutic uses of BPI protein products for human meningococcemia
BR9913645A (en) Combined therapies for B-cell lymphomas comprising administration of anti-cd20 antibody
BR9907189A (en) Products of the lipid fraction of the sea cucumber carotenoid and methods of use
UA32636C2 (en) Method for reducing cholesterol content in human blood serum
AR024074A1 (en) ABETA FRAGMENT JOINED WITH A BEARING PEPTIDE TO PREVENT OR TREAT DISEASES ASSOCIATED WITH ABETA AMILOID DEPOSITS, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND ITS USE IN THE PREPARATION OF MEDICINES.
DK0865294T3 (en) Methods for Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Preparations
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
NO20003550D0 (en) Pharmaceutical compositions and their use
NO933171L (en) Use of molecules targeting cell surface receptors for the treatment of viral diseases
ES2080307T3 (en) PHARMACEUTICAL COMPOSITIONS.
HUP9902429A2 (en) Modulators of tnf receptor associated factor (traf), their preparation and use
CA2062582A1 (en) Methods and substances for recruiting therapeutic agents to solid tissues
EP0797999A3 (en) Formulations of obesity protein
EP1003552A4 (en) LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
DE69719754D1 (en) THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
HUP0002062A2 (en) Method for diagnosing bone dysbolism
CO4820397A1 (en) TREATMENT AGAINST ASTHMA WITH TNFR -Ig
AU9363398A (en) Hepatitis c receptor protein cd81
Lopez-Gonzalez et al. Presence of the pineal hormone melatonin in rat cochlea: its variations with lighting conditions
DE69534633D1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF PUBLIC DISEASES
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
NO951762L (en) Stable preparation for the treatment of blood coagulation disorders, comprising an active coagulation promoter